
Thomas C Hanff

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8663095/publications.pdf Version: 2024-02-01



THOMAS C HANEE

#	Article	IF	CITATIONS
1	Thrombosis in <scp>COVID</scp> â€19. American Journal of Hematology, 2020, 95, 1578-1589.	4.1	235
2	ls There an Association Between COVID-19 Mortality and the Renin-Angiotensin System? A Call for Epidemiologic Investigations. Clinical Infectious Diseases, 2020, 71, 870-874.	5.8	202
3	Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respiratory Medicine,the, 2021, 9, 275-284.	10.7	198
4	Trends in Mechanical Support Use as a Bridge to Adult Heart Transplant Under New Allocation Rules. JAMA Cardiology, 2020, 5, 728.	6.1	48
5	Update to an early investigation of outcomes with the new 2018 donor heart allocation system in the United States. Journal of Heart and Lung Transplantation, 2020, 39, 725-726.	0.6	42
6	Clinical and Proteomic Correlates of Plasma ACE2 (Angiotensin-Converting Enzyme 2) in Human Heart Failure. Hypertension, 2020, 76, 1526-1536.	2.7	39
7	Coronavirus disease 2019 in heart transplant recipients: Risk factors, immunosuppression, and outcomes. Journal of Heart and Lung Transplantation, 2021, 40, 926-935.	0.6	36
8	Predicting Long Term Outcome in Patients Treated With Continuous Flow Left Ventricular Assist Device: The Penn—Columbia Risk Score. Journal of the American Heart Association, 2018, 7, .	3.7	30
9	Characteristics and Outcomes of COVID-19 in Patients on Left Ventricular Assist Device Support. Circulation: Heart Failure, 2021, 14, e007957.	3.9	24
10	Left Ventricular Assist Device as Destination Therapy: a State of the Science and Art of Long-Term Mechanical Circulatory Support. Current Heart Failure Reports, 2019, 16, 168-179.	3.3	20
11	Quantitative Proteomic Analysis of Diabetes Mellitus in Heart Failure With Preserved Ejection Fraction. JACC Basic To Translational Science, 2021, 6, 89-99.	4.1	18
12	Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans. PLoS ONE, 2021, 16, e0248080.	2.5	17
13	Multimodality assessment of heart failure with preserved ejection fraction skeletal muscle reveals differences in the machinery of energy fuel metabolism. ESC Heart Failure, 2021, 8, 2698-2712.	3.1	16
14	Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE) Tj ETQq0	00 ₂₉₀ BT /(Overlock 10 Tf 15
15	Relationship Between ACE2 and Other Components of the Renin-Angiotensin System. Current Hypertension Reports, 2020, 22, 44.	3.5	14
16	Assessment of Predictors of Left Atrial Volume Response to a Transcatheter InterAtrial Shunt Device (from the REDUCE LAP-HF Trial). American Journal of Cardiology, 2019, 124, 1912-1917.	1.6	13
17	The effect of transfusion of blood products on ventricular assist device support outcomes. ESC Heart Failure, 2020, 7, 3573-3581.	3.1	11
18	Response by Cohen et al to Letter Regarding Article, "Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19― Circulation Research, 2020, 126, e140-e141.	4.5	11

THOMAS C HANFF

#	Article	IF	CITATIONS
19	Comparison of Causes of Death After Heart Transplantation in Patients With Left Ventricular Ejection Fractions â‰ 9 5% Versus >35%. American Journal of Cardiology, 2016, 117, 1322-1326.	1.6	10
20	Prognostic Implications of Changes in Albumin Following Left Ventricular Assist Device Implantation in Patients With Severe Heart Failure. American Journal of Cardiology, 2017, 120, 2003-2007.	1.6	9
21	Coronavirus disease 2019 is delaying the diagnosis and management of chest pain, acute coronary syndromes, myocarditis and heart failure. Future Cardiology, 2021, 17, 3-6.	1.2	7
22	An Increasing Burden of Disease: Emergency Department Visits Among Patients With Ventricular Assist Devices From 2010 to 2017. Journal of the American Heart Association, 2021, 10, e018035.	3.7	7
23	Reply to Tedeschi et al. Clinical Infectious Diseases, 2020, 71, 901-901.	5.8	2
24	Association of Health Insurance Payer Type and Outcomes After Durable Left Ventricular Assist Device Implantation: An Analysis of the STS-INTERMACS Registry. Circulation: Heart Failure, 2021, 14, e008277.	3.9	1
25	Mental health disorders and emergency resource use and outcomes in ventricular assist device supported patients. American Heart Journal, 2021, 240, 11-15.	2.7	1
26	Novel Risk Model to Predict Emergency Department Associated Mortality for Patients Supported With a Ventricular Assist Device: The Emergency Department–Ventricular Assist Device Risk Score. Journal of the American Heart Association, 2022, 11, e020942.	3.7	1
27	Venoarterial Extracorporeal Membrane Oxygenation to Heart Transplant—An Inflamed Bridge?—Reply. JAMA Cardiology, 2021, 6, 362.	6.1	0